Phibro Animal Health – Q4 & Full Year 2026 Financial Analysis & Strategy

Phibro Animal Health Corporation (NASDAQ: PAHC) closed fiscal year 2026 (ended June 30, 2026) with top-line growth and operating leverage expansion. Full-year net sales hit $1.518 billion (up 17% YoY), while Adjusted EBITDA expanded 39% YoY to $255.0 million. This performance reflects both organic execution and initial synergies from its October 31, 2024 acquisition of Zoetis’ Medicated Feed Additives (MFA) portfolio.

PAHC Results At a Glance

Three core structural catalysts define the company’s financial profile heading into FY2027:

1. Successful Execution of ‘Phibro Forward’: The formal conclusion of PAHC’s three-year enterprise transformation program has structural cost efficiencies embedded across its operating divisions. Approximately 20% of projected FY2027 Adjusted EBITDA is directly attributable to recurring structural gains established via this initiative.

2. Post-MFA Footprint Rationalization: Management announced the planned shutdown of its Chicago Heights, IL manufacturing facility by summer 2027. This move consolidates production into existing internal plants and contract manufacturing organizations (CMOs) to eliminate capacity redundancies and protect long-term gross margins.

3. Derisked FY2027 Guidance Matrix: FY2027 guidance ($1.55B–$1.60B Net Sales; $258M–$268M Adjusted EBITDA) assumes near-zero sales contribution from its therapeutic antimicrobial virginiamycin in Brazil due to pending regulatory phase-outs. Any favorable regulatory resolution represents pure upside optionality.

FY2026 Financial Performance Breakdown – Fourth Quarter & Full-Year Scorecard

During Q4 FY2026, PAHC generated net sales of $396.7 million, representing a 5% YoY increase. Gross margin expanded 490 basis points YoY to 33.9% (or 34.6% on an adjusted basis, up 380 bps), driven by product mix shifts toward higher-margin Nutritional Specialties and a $4.3 million net benefit recovered through tariff mitigation efforts.

Income Statement Bridge (Q4 & FY2026)

Segment-Level Revenue & Operational Breakdown

1. Animal Health (Core Growth Driver)

Quarterly sales increased $5.1 million (+2% YoY) to $297.6 million, with adjusted gross profit rising by $20.6 million YoY.

• Medicated Feed Additives (MFAs) & Other: Generated $201.2 million (+1% YoY). High volume demand across the US ethanol performance business offset lower post-integration volumes within legacy acquired MFA product lines.

• Nutritional Specialties: Expanded 5% YoY to $52.5 million, propelled by dairy demand in North American commercial herds.

• Vaccines: Climbed 4% YoY to $43.9 million, anchored by poultry biologicals market expansion in Latin America and international demand out of Israel.

2. Mineral Nutrition

Generated $77.0 million, jumping 20% YoY (+$12.8M), behind high unit volume demand for elemental zinc and trace mineral trace mixes. However, segment gross profit contracted by $0.5 million YoY due to raw material input price inflation outstripping immediate pass-through pricing adjustments.

3. Performance Products

Remained flat to slightly positive at $22.2 million (+1% YoY). Broad-based industrial demand for copper-based chemical intermediates balanced persistent inventory destocking in personal care ingredient supply chains.

Chicago Heights Plant Closure

Following an evaluation of its global manufacturing footprint post-MFA acquisition, PAHC confirmed the planned closure of its Chicago Heights, Illinois plant, with production halting by Summer 2027.

• Workforce & Operations Impact: Approximately 100 positions will be phased out. Manufacturing lines will be integrated into PAHC-owned plants and domestic third-party CMOs.

• Capital Efficiency: Eliminates duplicate fixed overheads, lifts multi-year capacity utilization rates, and supports corporate gross margin targets toward 35.0%–36.0%.

Conclusion of “Phibro Forward”

June 30, 2026 marked the formal completion of Phibro Forward, the company’s 36-month enterprise optimization project.

• Structural EBITDA Contribution: Management estimates that approximately 1 out of every 5 dollars ($50M+) of projected FY2027 Adjusted EBITDA stems directly from permanent operational improvements created by the program.

• Execution Culture: Establishes permanent improvements in procurement, supply-chain forecasting, and organizational accountability under incoming leadership.

Guidance Matrix & FY2027 Outlook

For the fiscal year ending June 30, 2027, PAHC issued the following outlook:

FY2027 Guidance vs. FY2026 Actuals

Key Guidance Factors & Upside/Downside Risks

• Brazil Virginiamycin Regulatory Phase-Out: The guidance reflects conservative modeling regarding the regulatory status of therapeutic virginiamycin in Brazil. Despite ongoing discussions to secure required therapeutic indications before the current phase-out window expires, PAHC has modeled near-zero Brazilian virginiamycin revenues into its base plan. Any regulatory clearance serves as an unmodeled top- and bottom-line tailwind.

• Capital Structure & FX Pressure: Net interest expense expanded to $10.2 million in Q4 following the expiration of a favorable $300.0 million fixed-rate interest swap. Furthermore, foreign currency volatility—specifically in the Israeli New Shekel (ILS), Argentine Peso (ARS), and Euro (EUR)—drove $5.6 million in Q4 net FX losses, creating a non-operational headwind.

Investment Summary

Phibro Animal Health Corporation presents an attractive operational turnaround and cash-flow expansion story within the global animal health sector.

• EBITDA Margin Discipline: By generating $255 million in FY2026 Adjusted EBITDA and targeting up to $268 million in FY2027, PAHC is converting post-acquisition revenues into free cash flow.

• Footprint Optimization: Moving swiftly to close the Chicago Heights site demonstrates management’s commitment to optimizing asset efficiency post-MFA transaction.

• Conservative Guidance Baseline: Derisking the guidance matrix against regulatory outcomes in Brazil lowers near-term earnings surprise risk while leaving room for potential upside.

Consensus View: PAHC’s combination of operational discipline (Phibro Forward), footprint rationalization (Chicago Heights consolidation), and conservative guidance setup provides a solid foundation for top-line expansion and mid-teens EPS growth through FY2027.